Herantis Pharma Oyj tiedottaa onnistuneesta noin 5,8 miljoonan euron suunnatusta osakeannista
March 12, 2019 11:00 ET
|
Herantis Pharma Oyj
Herantis Pharma Oyj tiedottaa onnistuneesta noin 5,8 miljoonan euron suunnatusta osakeannista Herantis Pharma Oyj Yhtiötiedote 12.3.2019 kello 17:00 Ei julkistettavaksi tai levitettäväksi, suoraan...
Herantis Pharma Plc Announces Positive Outcome of Directed Share Issue Raising EUR 5.8 Million
March 12, 2019 11:00 ET
|
Herantis Pharma Oyj
Herantis Pharma Plc Announces Positive Outcome of Directed Share Issue Raising EUR 5.8 Million Herantis Pharma Plc Company release 12 March 2019, 5:00 pm Not for publication or distribution,...
Story of Traumatic Brain Injury Wins #IAmInvisibleNoMore Video Contest
May 04, 2018 17:10 ET
|
Allsup
Belleville, Illinois, May 04, 2018 (GLOBE NEWSWIRE) -- The Invisible Disabilities Association (IDA), an organization dedicated to raising worldwide awareness of invisible disabilities, and Allsup,...
New Genetic Mutation Discovery Sheds Light on Anemia Disease
March 03, 2016 12:36 ET
|
ARUP Laboratories
SALT LAKE CITY, March 3, 2016 (GLOBE NEWSWIRE) -- Using whole exome sequencing, which sequences all expressed genes in a genome, Rong Mao, MD, and Pinar Bayrak-Toydemir, MD, PhD, discovered a new...
Laurantis Pharma and Ark Therapeutics Sign Manufacturing Agreement for Production of Lymfactin(TM) Investigational Treatment for Breast Cancer-Associated Lymphedema
October 15, 2012 08:00 ET
|
Laurantis Pharma Oy; Ark Therapeutics Group plc
LONDON and TURKU, FINLAND--(Marketwire - Oct 15, 2012) - Ark Therapeutics has been selected to manufacture and supply Lymfactin™ to Laurantis Pharma under a conditional agreement...
U.S. Patent Office Issues Patent to Laurantis for Cis-UCA as a Treatment for Bladder Cancer
October 09, 2012 08:00 ET
|
Laurantis Pharma OY
TURKU, FINLAND--(Marketwire - Oct 9, 2012) - The United States Patent and Trademark Office has allowed a patent application by Laurantis Pharma Oy (Laurantis) for the use of cis-urocanic acid...
Laurantis Pharma Completes Funding Round for Research Program
September 04, 2012 07:59 ET
|
Laurantis Pharma OY
BOSTON, MA and TURKU, FINLAND--(Marketwire - Sep 4, 2012) - Laurantis Pharma today announced successful completion of a funding round, which raised EUR 5.64 million (US$7.02 million). A...
Investigational Cis-urocanic Acid Eye Drops for Dry Eye Syndrome Well Tolerated, in Phase 1 Clinical Study
June 28, 2012 10:03 ET
|
Laurantis Pharma OY
TURKU, FINLAND--(Marketwire - Jun 28, 2012) - Laurantis Pharma today announced that it has completed a phase 1 clinical study with its Cis-urocanic acid eye drops. The objective of the study was to...
Research Team Discovers Four-Fold Improvement in Ability to Restore Lymphatic Function With Adenovirally-Delivered VEGF-C Gene Therapy After Lymph Node Transplant Surgery Compared to the Surgery Alone
March 06, 2012 14:30 ET
|
Laurantis Pharma OY
VENTURA, CA--(Marketwire - Mar 6, 2012) - Lymphedema Awareness Day was established to support the needs of patients with lymphedema and to raise awareness for the need to develop new treatment...
Lymfactin(TM) Found to Significantly Increase Growth of Lymphatic Vessels in Animal Study; Results Seen as "Pathway to a Breakthrough" for Breast Cancer Patients Who Would Benefit From Lymph Node Transfers for Lymphedema
September 23, 2011 05:00 ET
|
Laurantis Pharma
MALMO, SWEDEN--(Marketwire - Sep 23, 2011) - Laurantis Pharma, a privately held biotechnology company based in Finland, today announced that Lymfactin™, adenoviral VEGF-C growth factor...